NewsVandana Singh
Vanda Pharmaceuticals
VNDA · NASDAQ
$4.17+$0.08 (+1.96%)TodayMarket closed ·
Prev close $4.09
Latest news
- Press releasePRNewswire
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
- NewsVandana Singh
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
- News
Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis
- Press releasePRNewswire
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
- Press releasePRNewswire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
- Press releasePRNewswire
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
- News
Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis
- Press releasePRNewswire
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
- Press releasePRNewswire
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
- Press releasePRNewswire
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
- News
Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
- News
Earnings Scheduled For May 6, 2026
- Press releasePRNewswire
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
- Press releasePRNewswire
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
- Press releasePRNewswire
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
- Press releasePRNewswire
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
- Press releasePRNewswire
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
- Press releasePRNewswire
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
- Press releasePRNewswire
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
- Press releasePRNewswire
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
- NewsVandana Singh
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
- Press releasePRNewswire
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- NewsVandana Singh
What's Going On With Vanda Pharma Stock Tuesday?
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday
- NewsRishabh Mishra
Stock Market Today: Dow Jones, S&P500, Nasdaq Futures Decline After SC Strikes Down Trump's Emergency Tariffs— NVO, MSTR, VNDA In Focus (UPDATED)
- News
Analyst Expectations For Vanda Pharmaceuticals's Future
- NewsAvi Kapoor
Rollins Posts Downbeat Results, Joins Paycom Software, Cisco, Applovin And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
Earnings Scheduled For February 11, 2026
- News
Earnings Outlook For Vanda Pharma
- NewsAvi Kapoor
S&P 500 Falls For Fourth Session But Records Gains In 2025: Investor Sentiment Declines, Fear & Greed Index Remains In 'Neutral Zone
- NewsAvi Kapoor
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply
- NewsAvi Kapoor
Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- NewsAvi Kapoor
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
- NewsAvi Kapoor
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Vanda Pharmaceuticals, One Stop Systems And 3 Stocks To Watch Heading Into Wednesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.